CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blueprint Medicines, a company harnessing the understanding of the molecular blueprint of cancer to develop personalized, highly-selective cancer therapies, today announced the addition of George Demetri, M.D., as a clinical advisor and member of the scientific advisory board. Dr. Demetri is the director of the Ludwig Center at the Dana-Farber/Harvard Cancer Center and senior vice president for experimental therapeutics at the Dana-Farber Cancer Institute in Boston.
